Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Wyeth Menopause TV Ads To Continue Unchanged After JAMA Article

  • News

Executive Summary

Wyeth-Ayerst plans to continue its menopause research ads that include a reference to studies on the link between Alzheimer's disease and menopause.

You may also be interested in...



Wyeth Prempro Gets Dementia Warning; FDA Considering HRT Class Labeling

FDA is considering hormone replacement therapy class labeling that would incorporate data from a WHI sub-study showing twice the rate of dementia in patients taking Wyeth's Prempro estrogen/progestin combo

Wyeth Prempro Gets Dementia Warning; FDA Considering HRT Class Labeling

FDA is considering hormone replacement therapy class labeling that would incorporate data from a WHI sub-study showing twice the rate of dementia in patients taking Wyeth's Prempro estrogen/progestin combo

Premarin Alzheimer's Prevention Studies Urged; Treatment Trial Negative

A trial finding no effect for Premarin in the treatment of Alzheimer's does not rule out a role for estrogen replacement therapy in prevention of the disease, Wyeth-Ayerst and the study authors pointed out.

Table

View full table

Tags:
Latest Headlines

Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director

Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works

ADHD Drugs: FDA Commissioner Blames Inappropriate Prescribing For Shortages

Moment Of Truth For Seven EU Filings; Cytokinetics To Make Its Case For Heart Failure Drug

See All
UsernamePublicRestriction

Register

PS035682

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By